Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: A 26‐week randomized, placebo‐controlled, double‐blind trial
- 17 July 2002
- journal article
- clinical trial
- Published by Wiley in Annals of Neurology
- Vol. 52 (3) , 346-350
- https://doi.org/10.1002/ana.10292
Abstract
In a randomized, placebo‐controlled, double‐blind study, we investigated whether statins alter cholesterol metabolites and reduce Aβ levels in the cerebrospinal fluid of 44 patients with Alzheimer's disease. Individuals were given up to 80mg simvastatin daily or placebo for 26 weeks. Overall, simvastatin did not significantly alter cerebrospinal fluid levels of Aβ40 and Aβ42. In post hoc analysis, simvastatin significantly decreased Aβ40 levels in the cerebrospinal fluid of patients with mild Alzheimer's disease. The reduction of Aβ40 correlated with the reduction of 24S‐hydroxycholesterol. These changes were not observed in more severely affected patients.Keywords
Funding Information
- MSD
- Bundesministerium für Bildung, Forschung, Wissencraft und Technologie (01EC9402)
This publication has 18 references indexed in Scilit:
- A Cholesterol-Lowering Drug Reduces β-Amyloid Pathology in a Transgenic Mouse Model of Alzheimer's DiseaseNeurobiology of Disease, 2001
- Cholesterol and Alzheimer’s diseaseNeurology, 2001
- A fluid connection: Cholesterol and AβProceedings of the National Academy of Sciences, 2001
- Simvastatin strongly reduces levels of Alzheimer's disease β-amyloid peptides Aβ42 and Aβ40 in vitro and in vivoProceedings of the National Academy of Sciences, 2001
- Cholesterol depletion inhibits the generation of β-amyloid in hippocampal neuronsProceedings of the National Academy of Sciences, 1998
- Cholesterol homeostasis in human brain: evidence for an age-dependent flux of 24S-hydroxycholesterol from the brain into the circulation.Proceedings of the National Academy of Sciences, 1996
- Reduction of β‐amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's diseaseAnnals of Neurology, 1995
- Clinical implications of the biopharmaceutical properties of fluvastatinThe American Journal of Cardiology, 1994
- Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease.Proceedings of the National Academy of Sciences, 1993
- Rates of cholesterol, ubiquinone, dolichol and dolichyl‐P biosynthesis in rat brain slicesFEBS Letters, 1990